{"id":"NCT01702363","sponsor":"GlaxoSmithKline","briefTitle":"Long-term Safety Study for GSK573719 in Japanese","officialTitle":"A 52-week, Multi-centre, Open-label Study to Evaluate the Safety and Tolerability of GSK573719 125 mcg Once-daily Via Novel Dry Powder Inhaler (nDPI) in Japanese Subjects With Chronic Obstructive Pulmonary Disease.","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2012-08","primaryCompletion":"2013-12","completion":"2013-12","firstPosted":"2012-10-08","resultsPosted":"2014-08-08","lastUpdate":"2017-01-09"},"enrollment":131,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Pulmonary Disease, Chronic Obstructive"],"interventions":[{"type":"DRUG","name":"GSK573719","otherNames":[]}],"arms":[{"label":"GSK573719","type":"EXPERIMENTAL"}],"summary":"The objective of this study is to evaluate the safety and tolerability of GSK573719 Inhalation Powder 125 mcg once-daily over 52 weeks in Japanese subjects with COPD.","primaryOutcome":{"measure":"Number of Participants With Any Adverse Event (AE) or Any Serious Adverse Event (SAE) Throughout the Treatment Period","timeFrame":"From the first dose of study medication up to 52 weeks","effectByArm":[{"arm":"UMEC 125 Âµg QD","deltaMin":105,"sd":null}],"pValues":[]},"eligibility":{"minAge":"40 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":7,"exclusionCount":17},"locations":{"siteCount":20,"countries":["Japan"]},"refs":{"pmids":["26782971"],"seeAlso":["https://www.clinicalstudydatarequest.com"]},"adverseEventsSummary":{"seriousAny":{"events":17,"n":131},"commonTop":["Nasopharyngitis","Constipation","Bronchitis","Upper respiratory tract inflammation","Pharyngitis"]}}